Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Leadership & People

Set Alert for Leadership & People

Executives On The Move: Sypre Therapeutics, Evelo Biosciences, Amylyx Pharmaceuticals And More

Recent executive moves in the industry include changes at the top at Spyre Therapeutics, Neopharmed Gentili and CytoDyn.

Executive Changes Leadership

Novartis Has A New Goal: $2bn Peak Sales Per Product

The company said during its R&D day that it has culled its pipeline to 103 clinical stage assets, choosing to focus on drugs that could be big blockbusters.

Research & Development Business Strategies

Astellas India MD On Action-Packed Run Ahead, Breaking The Glass Ceiling

In an interview with Scrip, Astellas’s India chief outlines how the Japanese company expects to build out its operations in the country, with a flurry of key launches in the wings. She also shares vignettes of her own career path, which has not been a bed of roses.

India Commercial

Scrip Awards Lifetime Achievement Winner Jeremy Levin Urges Pharma To Put Humanity First

In accepting Scrip’s Lifetime Achievement Award, Ovid Therapeutics’ CEO called on pharma to show responsible leadership and live up to its potential to do good for society.

Leadership Strategy

Executives On The Move: New CEOs at Novavax, Homology Medicines, Race Oncology And More

Recent moves in the industry include internal rejigs at Homology Medicines, Virpax Pharmaceuticals, CytoDyn and Applied Therapeutics, plus new board members at Neuroscientific Biopharmaceuticals.

Executive Changes Leadership

Executives On The Move: New C-Suite Changes At Amneal Pharmaceuticals, Lexicon Pharmaceuticals And Amicus Therapeutics

Recent moves in the industry include changes at the top at Amneal Pharmaceuticals, plus new CEOs at Incendia Therapeutics and Nereid Therapeutics.

Executive Changes Leadership

Norway’s Nykode Eyes NASDAQ As Pipeline Advances

CEO Michael Engsig tells Scrip that his well-capitalized company has ambitious plans for US expansion and is looking to set up an autoimmune diseases arm to add to its oncology efforts.

Business Strategies Vaccines

Novartis Casts Nets Globally To Snap Up Best Assets

The Swiss major’s business development chief Susanne Kreutz tells Scrip that geography is no barrier for her team in the search for promising licensing deals or bolt-on acquisitions.

Business Strategies Deals

Executives On The Move: C-Suite Changes At Astellas Pharma Plus New CEOs For Three Firms

Recent executive moves in the industry include changes at the C-suite at Astellas Pharma, plus new CEOs at Y-mAbs Therapeutics, Ocuphire Pharma and Neopharmed Gentili.

Executive Changes Leadership

The Next Frontier In Obesity: Better, Not More, Weight Loss

R&D leaders from Novo Nordisk, Lilly, Boehringer Ingelheim and others discussed what some of the advances could be in the next generation of obesity medicines.

Metabolic Disorders Research & Development

BioMarin’s Bienaimé To Retire With Sales And Earnings Growth On Track

Genentech CEO Alexander Hardy will succeed Jean-Jacques Bienaimé, who has led the rare disease specialist for 18 years. Gene therapy Roctavian has gotten off to a slow commercial start.

Leadership Business Strategies

Executives On The Move: Change At The Top For BMS Among other New CEOs

Recent executive moves in the industry include new CEOs at Viridian Therapeutic, Opthea and Gyre Therapeutics, while Bristol Myers Squibb confirms its new leadership. 

Executive Changes Leadership
See All